Is NBP or AURA more profitable?

I-Mab's return on equity of 0.00% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets I-Mab N/A N/A N/A Aura Biosciences N/A -78.12% -64.08%

Is NBP or DRUG more profitable?

I-Mab's return on equity of 0.00% beat Bright Minds Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets I-Mab N/A N/A N/A Bright Minds Biosciences N/A -20.58% -20.25%

Is NBP or CADL more profitable?

I-Mab's return on equity of 0.00% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets I-Mab N/A N/A N/A Candel Therapeutics N/A -60.42% -41.33%

Which has stronger valuation and earnings, NBP or RIGL?

Rigel Pharmaceuticals has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio I-Mab $3.89M 47.87 -$46.27M -$0.36 N/A Rigel Pharmaceuticals $294.28M 2.35 $367.02M $18.72 2.00

I-Mab (NBP) Competitors

$1.61 +0.01 (+0.63%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$1.64 +0.02 (+1.55%)

As of 09:05 AM Eastern

Compare

NBP vs. ACRS, AURA, DRUG, CADL, and RIGL

Should you buy I-Mab stock or one of its competitors? MarketBeat compares I-Mab with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with I-Mab include Aclaris Therapeutics (ACRS), Aura Biosciences (AURA), Bright Minds Biosciences (DRUG), Candel Therapeutics (CADL), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "biotechnology" industry.

How does I-Mab compare to Aclaris Therapeutics?

I-Mab (NASDAQ:NBP) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

In the previous week, Aclaris Therapeutics had 3 more articles in the media than I-Mab. MarketBeat recorded 3 mentions for Aclaris Therapeutics and 0 mentions for I-Mab. Aclaris Therapeutics' average media sentiment score of 1.24 beat I-Mab's score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
I-Mab	Neutral
Aclaris Therapeutics	Positive

I-Mab has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. I-Mab's return on equity of 0.00% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

I-Mab currently has a consensus target price of $9.00, suggesting a potential upside of 459.01%. Aclaris Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 107.96%. Given I-Mab's higher possible upside, analysts plainly believe I-Mab is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

38.4% of I-Mab shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 22.1% of I-Mab shares are owned by company insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

I-Mab has higher earnings, but lower revenue than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	47.87	-$46.27M	-$0.36	N/A
Aclaris Therapeutics	$7.83M	98.64	-$64.92M	-$0.56	N/A

I-Mab has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

Summary

I-Mab beats Aclaris Therapeutics on 9 of the 17 factors compared between the two stocks.

How does I-Mab compare to Aura Biosciences?

I-Mab (NASDAQ:NBP) and Aura Biosciences (NASDAQ:AURA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

I-Mab presently has a consensus price target of $9.00, indicating a potential upside of 459.01%. Aura Biosciences has a consensus price target of $20.50, indicating a potential upside of 191.19%. Given I-Mab's higher possible upside, equities analysts plainly believe I-Mab is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

I-Mab's return on equity of 0.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Aura Biosciences	N/A	-78.12%	-64.08%

I-Mab has higher revenue and earnings than Aura Biosciences. I-Mab is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	47.87	-$46.27M	-$0.36	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

I-Mab has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

38.4% of I-Mab shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 22.1% of I-Mab shares are owned by company insiders. Comparatively, 1.9% of Aura Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, I-Mab's average media sentiment score of 0.00 equaled Aura Biosciences'average media sentiment score.

Company	Overall Sentiment
I-Mab	Neutral
Aura Biosciences	Neutral

Summary

I-Mab beats Aura Biosciences on 8 of the 12 factors compared between the two stocks.

How does I-Mab compare to Bright Minds Biosciences?

I-Mab (NASDAQ:NBP) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

38.4% of I-Mab shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 22.1% of I-Mab shares are owned by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

I-Mab's return on equity of 0.00% beat Bright Minds Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Bright Minds Biosciences	N/A	-20.58%	-20.25%

Bright Minds Biosciences has lower revenue, but higher earnings than I-Mab. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	47.87	-$46.27M	-$0.36	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A

I-Mab presently has a consensus target price of $9.00, suggesting a potential upside of 459.01%. Bright Minds Biosciences has a consensus target price of $143.83, suggesting a potential upside of 94.95%. Given I-Mab's higher probable upside, analysts plainly believe I-Mab is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bright Minds Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

I-Mab has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.27, suggesting that its stock price is 627% less volatile than the broader market.

In the previous week, Bright Minds Biosciences had 6 more articles in the media than I-Mab. MarketBeat recorded 6 mentions for Bright Minds Biosciences and 0 mentions for I-Mab. Bright Minds Biosciences' average media sentiment score of 1.58 beat I-Mab's score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
I-Mab	Neutral
Bright Minds Biosciences	Very Positive

Summary

Bright Minds Biosciences beats I-Mab on 8 of the 15 factors compared between the two stocks.

How does I-Mab compare to Candel Therapeutics?

I-Mab (NASDAQ:NBP) and Candel Therapeutics (NASDAQ:CADL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

In the previous week, Candel Therapeutics had 4 more articles in the media than I-Mab. MarketBeat recorded 4 mentions for Candel Therapeutics and 0 mentions for I-Mab. Candel Therapeutics' average media sentiment score of 0.19 beat I-Mab's score of 0.00 indicating that Candel Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
I-Mab	Neutral
Candel Therapeutics	Neutral

38.4% of I-Mab shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 22.1% of I-Mab shares are held by insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Candel Therapeutics has lower revenue, but higher earnings than I-Mab. Candel Therapeutics is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	47.87	-$46.27M	-$0.36	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

I-Mab's return on equity of 0.00% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Candel Therapeutics	N/A	-60.42%	-41.33%

I-Mab has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.51, meaning that its share price is 151% less volatile than the broader market.

I-Mab presently has a consensus price target of $9.00, indicating a potential upside of 459.01%. Candel Therapeutics has a consensus price target of $18.57, indicating a potential upside of 84.42%. Given I-Mab's higher probable upside, equities analysts clearly believe I-Mab is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

I-Mab beats Candel Therapeutics on 9 of the 14 factors compared between the two stocks.

How does I-Mab compare to Rigel Pharmaceuticals?

I-Mab (NASDAQ:NBP) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

In the previous week, Rigel Pharmaceuticals had 8 more articles in the media than I-Mab. MarketBeat recorded 8 mentions for Rigel Pharmaceuticals and 0 mentions for I-Mab. Rigel Pharmaceuticals' average media sentiment score of 0.98 beat I-Mab's score of 0.00 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
I-Mab	Neutral
Rigel Pharmaceuticals	Positive

Rigel Pharmaceuticals has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	47.87	-$46.27M	-$0.36	N/A
Rigel Pharmaceuticals	$294.28M	2.35	$367.02M	$18.72	2.00

I-Mab currently has a consensus price target of $9.00, indicating a potential upside of 459.01%. Rigel Pharmaceuticals has a consensus price target of $54.50, indicating a potential upside of 45.61%. Given I-Mab's higher probable upside, analysts clearly believe I-Mab is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Rigel Pharmaceuticals has a net margin of 121.50% compared to I-Mab's net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 47.99% beat I-Mab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Rigel Pharmaceuticals	121.50%	47.99%	32.40%

38.4% of I-Mab shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 22.1% of I-Mab shares are owned by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

I-Mab has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

Summary

Rigel Pharmaceuticals beats I-Mab on 12 of the 16 factors compared between the two stocks.

Get I-Mab News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBP vs. The Competition

Export

Metric	I-Mab	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$185.04M	$3.55B	$6.86B	$12.43B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-4.47	7.29	280.72	24.99
Price / Sales	47.87	1,271.79	645.01	112.42
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	0.81	16.69	10.94	6.21
Net Income	-$46.27M	-$12.54M	$3.48B	$347.49M
7 Day Performance	-8.00%	0.25%	0.80%	1.28%
1 Month Performance	-24.77%	-7.46%	-4.17%	-3.62%
1 Year Performance	N/A	47.08%	61.47%	18.37%

I-Mab Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBP I-Mab	1.6789 of 5 stars	$1.61 +0.6%	$9.00 +459.0%	N/A	$185.04M	$3.89M	N/A	380
ACRS Aclaris Therapeutics	2.0984 of 5 stars	$5.20 -2.3%	$11.50 +121.2%	+261.4%	$743.01M	$7.83M	N/A	100	Positive News Upcoming Earnings
AURA Aura Biosciences	2.0785 of 5 stars	$7.01 -1.4%	$20.50 +192.4%	+4.5%	$735.08M	N/A	N/A	50
DRUG Bright Minds Biosciences	2.933 of 5 stars	$73.26 -1.8%	$143.83 +96.3%	+119.4%	$726.31M	N/A	N/A	N/A	Positive News
CADL Candel Therapeutics	2.7761 of 5 stars	$10.01 +1.4%	$18.57 +85.5%	+60.1%	$723.18M	N/A	N/A	60	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBP) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

I-Mab (NBP) Competitors

NBP vs. ACRS, AURA, DRUG, CADL, and RIGL

How does I-Mab compare to Aclaris Therapeutics?

Summary

How does I-Mab compare to Aura Biosciences?

Summary

How does I-Mab compare to Bright Minds Biosciences?

Summary

How does I-Mab compare to Candel Therapeutics?

Summary

How does I-Mab compare to Rigel Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBP vs. The Competition

I-Mab Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

I-Mab (NBP) Competitors

NBP vs. ACRS, AURA, DRUG, CADL, and RIGL

How does I-Mab compare to Aclaris Therapeutics?

Does the media refer more to NBP or ACRS?

Is NBP or ACRS more profitable?

Do analysts recommend NBP or ACRS?

Do institutionals & insiders hold more shares of NBP or ACRS?

Which has better earnings and valuation, NBP or ACRS?

Which has more risk and volatility, NBP or ACRS?

Summary

How does I-Mab compare to Aura Biosciences?

Do analysts rate NBP or AURA?

Is NBP or AURA more profitable?

Which has preferable earnings & valuation, NBP or AURA?

Which has more risk & volatility, NBP or AURA?

Do institutionals & insiders believe in NBP or AURA?

Does the media refer more to NBP or AURA?

Summary

How does I-Mab compare to Bright Minds Biosciences?

Do institutionals & insiders hold more shares of NBP or DRUG?

Is NBP or DRUG more profitable?

Which has preferable valuation and earnings, NBP or DRUG?

Do analysts prefer NBP or DRUG?

Which has more volatility & risk, NBP or DRUG?

Does the media favor NBP or DRUG?

Summary

How does I-Mab compare to Candel Therapeutics?

Does the media prefer NBP or CADL?

Do institutionals and insiders believe in NBP or CADL?

Which has preferable valuation & earnings, NBP or CADL?

Is NBP or CADL more profitable?

Which has more volatility & risk, NBP or CADL?

Do analysts recommend NBP or CADL?

Summary

How does I-Mab compare to Rigel Pharmaceuticals?

Does the media prefer NBP or RIGL?

Which has stronger valuation and earnings, NBP or RIGL?

Do analysts prefer NBP or RIGL?

Is NBP or RIGL more profitable?

Do institutionals & insiders believe in NBP or RIGL?

Which has more volatility & risk, NBP or RIGL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBP vs. The Competition

I-Mab Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools